We are live on ! Find out more
CA

CHI Advisors Portfolio holdings

AUM $252M
1-Year Est. Return 56.99%
This Fund
S&P 500
This Quarter Est. Return
-7.97%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$252M
AUM Growth
-$77.3M
Cap. Flow
+$26.1M
Cap. Flow %
10.33%
Top 10 Hldgs %
81.34%
Holding
31
New
5
Increased
9
Reduced
8
Closed
3

Top Buys

1
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$62.6M
2
MLYS icon
Mineralys Therapeutics
MLYS
+$7.41M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$5.15M
4
BPMC
Blueprint Medicines
BPMC
+$4.96M
5
SGMT icon
Sagimet Biosciences
SGMT
+$4.64M

Top Sells

1
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$46.9M
2
SLRN
ACELYRIN
SLRN
+$8.51M
3
IRON icon
Disc Medicine
IRON
+$5.01M
4
PLRX icon
Pliant Therapeutics
PLRX
+$1.78M
5
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$1.62M

Sector Composition

1 Healthcare 98.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DTIL icon
26
Precision BioSciences
DTIL
$215M
$207K 0.08%
20,221
-33,231
-62% -$511K
RPTX
27
CALL
DELISTED
Repare Therapeutics
RPTX
$158K 0.06%
+50,000
New +$516K
PLRX icon
28
CALL
Pliant Therapeutics
PLRX
$68.7M
$55K 0.02%
137,500
+7,200
+6% +$125K
CRVS icon
29
Corvus Pharmaceuticals
CRVS
$1.2B
– –
-200,000
Closed -$458K
HOOK
30
DELISTED
HOOKIPA Pharma
HOOK
– –
-78,874
Closed -$694K
VECT
31
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
– –
-2,782,756
Closed -$46.9M
1
2

Similar funds

SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
T
TRUADVICE Sarasota, Florida $255M AUM 14.45% 1-Year Est. Return
W
WealthOne Albany, New York $248M AUM 17.79% 1-Year Est. Return
RBGI
Ribbit Bullfrog GP II Palo Alto, California $258M AUM 33.43% 1-Year Est. Return
TOGEPT
Trustees of General Electric Pension Trust Norwalk, Connecticut $245M AUM 128.88% 1-Year Est. Return
IAM
Innovis Asset Management Chicago, Illinois $260M AUM 28.13% 1-Year Est. Return
RCGI
Ribbit Capital GP II Palo Alto, California $260M AUM 2.87% 1-Year Est. Return
AEPLI
AH Equity Partners LSV III Menlo Park, California $262M AUM 59.24% 1-Year Est. Return

CHI Advisors's Q3 2023 Portfolio in Review

As of Q3 2023, CHI Advisors held 31 positions worth $252M, down 23% from $330M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

CHI Advisors deployed $26.1M of net new capital in Q3 2023, opening 5 new positions and adding to 9 existing holdings. Its largest new stake was Mineralys Therapeutics: 568,379 shares worth $5.41M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was ACELYRIN, an estimated $8.51M trimmed.

  • CHI Advisors's largest Q3 2023 buy was Mineralys Therapeutics: 568,379 shares worth $5.41M.
  • CHI Advisors added most to Orchard Therapeutics plc American Depositary Shares in Q3 2023, an estimated $62.6M increase.
  • CHI Advisors's biggest Q3 2023 reduction was ACELYRIN, cutting an estimated $8.51M.
  • CHI Advisors fully exited VectivBio Holding AG Ordinary Shares in Q3 2023, selling an estimated $46.9M.
  • CHI Advisors's ten largest holdings make up 81% of its $252M portfolio in Q3 2023.
  • CHI Advisors opened 5 new positions and closed 3 in Q3 2023.
  • CHI Advisors's portfolio value fell 23% quarter-over-quarter to $252M.

Based on CHI Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.